ELTX experienced a dramatic 92% revenue collapse from $28.3M to $2.3M while simultaneously achieving a remarkable turnaround from -$11.3M stockholders equity deficit to +$1.6M positive equity.
The massive revenue decline suggests a fundamental shift in the business model or loss of major revenue streams, which is particularly concerning for a biotech company. However, the dramatic improvement in equity position and reduced liabilities indicates potential debt restructuring, equity raises, or asset optimization that has strengthened the balance sheet despite operational challenges.
ELTX shows a tale of two stories - operational deterioration with revenue plummeting 92% but significant balance sheet improvement with stockholders equity swinging positive by $12.9M and total liabilities declining 39%. The company reduced cash burn as evidenced by improved net losses (-24% improvement) and lower R&D spending, while dramatically cutting interest expense by 71%, suggesting debt restructuring. This financial profile indicates a company that has likely undergone significant capital restructuring to weather a major business transition or setback.
Equity base grew 114.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Revenue declined 91.9% — significant demand weakness or market share loss warrants investigation.
Capex reduced 81.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Liabilities reduced 38.7% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
R&D spending cut 26% — could signal cost discipline or concerning reduction in innovation investment.
Net income grew 23.8% — bottom-line growth signals improving overall business health.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →